ArticleJournal of Taibah University Medical Sciences2025
Efficacy of immediate-release versus extended-release metformin on glycemic control and insulin resistance in Saudi patients with type 2 diabetes: A prospective cohort study.
Article in Journal of Taibah University Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing metformin therapy in Saudi patients: The crucial role of vitamin B12 monitoring and medication adherence.Journal of Taibah University Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Metformin, the first-line treatment for type 2 diabetes mellitus (T2DM), is available in both immediate-release (IR) and extended-release (XR) formulations. Limited data exist comparing their effects on glycemic control and insulin resistance among Saudi patients. This study aims to evaluate the impact of metformin IR versus XR on glycated hemoglobin (HbA1c), fasting blood glucose (FBG), fasting serum insulin (FSI), and insulin resistance (HOMA-IR) in newly diagnosed Saudi T2DM patients. Methods: In a 6-month prospective cohort study at a Saudi diabetes center, 119 adults with newly diagnosed T2DM (62 on metformin IR, 57 on metformin XR) were followed. Glycemic parameters (HbA1c, FBG) and insulin resistance indices (FSI, HOMA-IR) were measured at baseline and after a 6-month follow-up. Within-group changes were assessed, and outcomes were compared between the IR and XR groups. Results: Both formulations significantly improved glycemic control from baseline. HbA1c was reduced from 7.3 % at baseline to ∼6.5 % with metformin XR, versus ∼7.6 %-∼7.2 % with metformin IR. XR achieved a greater adjusted mean HbA1c reduction by 31 % than IR (p < 0.05). FBG improved in both groups with no significant statistical difference between groups (p = 0.111). Despite better glycemic declines with XR, FSI and HOMA-IR improved substantially with no statistically significant difference between groups (p > 0.05). Conclusions: In newly diagnosed Saudi patients with T2DM, metformin XR showed better reduction in long-term glycemic control compared to IR, while both formulations similarly reduced insulin levels and resistance. XR's enhanced glycemic efficacy, achieved without differences in insulin resistance effects, may reflect improved adherence and sustained drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.